上海有临医药科技有限公司

Chinese contract research organisation established on 10 January 2017 in Shanghai, describing itself as a digitalised CRO focused on oncology, autoimmune disease, infection, neurology and cardiovascular disease and using intelligent technology to meet the demand for fast iteration, dynamic decision making and good value in new drug clinical development. Provides integrated services across the whole clinical trial process including strategy consulting, regulatory filing, medical affairs, clinical operations, data management and statistics, clinical pharmacology, pharmacovigilance, independent imaging review, bioanalysis, site management and staff secondment, and is also active as a radiopharmaceutical CRO. Runs a team of more than two hundred people with six subsidiaries and works with over two thousand clinical experts and a thousand research centres across twenty-eight provinces and municipalities.